FibroGen Inc (FGEN)

13.28
-0.04(-0.30%)
After Hours
13.08
-0.20(-1.51%)
- Real-time Data
  • Volume:
    604,331
  • Bid/Ask:
    13.00/13.38
  • Day's Range:
    13.03 - 13.39

FGEN Overview

Prev. Close
13.32
Day's Range
13.03-13.39
Revenue
190.35M
Open
13.35
52 wk Range
12.55-57.21
EPS
-2.03
Volume
604,331
Market Cap
1.22B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,261,240
P/E Ratio
-
Beta
0.94
1-Year Change
-68.69%
Shares Outstanding
92,128,227
Next Earnings Date
Aug 09, 2021
What is your sentiment on FibroGen Inc?
or
Market is currently closed. Voting is open during market hours.

FibroGen Inc News

FibroGen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsStrong SellBuyBuyStrong SellStrong Sell
SummaryStrong SellNeutralNeutralStrong SellStrong Sell

FibroGen Inc Company Profile

FibroGen Inc Company Profile

Sector
Services
Employees
599

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Read More
  • Target for today?
    1
    • Balance Sheet looks good. They hit rock bottom under 20. just need some good news and then .... 🚀🌙
      1
      • Target guys ?
        1
        • $19
          0
        • 28
          0
      • Not bad
        1
        • 21 today
          3
          • Run baby
            2
            • Go to the moon
              1
              • Soounds like good news!
                0
                • FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy 🚀🚀
                  0
                  • 16-15 next level)
                    7
                    • No seas cenizo !!!
                      0
                  • Rip my 22.4
                    0
                    • I just bought 10k :)
                      0
                      • Same
                        0
                      • Same!!! @18.9
                        0
                    • They'll be back. I bought at 20 and will forget about it for a while.
                      0
                      • Nice! Jan 2022 option $17.50 strike.
                        0
                    • rebound from 16.34
                      0
                      • you will lose anyway
                        1
                        • Going to $30 this week. hold
                          0
                          • Added more today at 19.05
                            0
                            • good for 35
                              0
                              • strong sell
                                0
                                • Just bought 21.05 good for long term
                                  1
                                  • Love the guys who bought this stock 60$
                                    3
                                    • the earning is negative and FDA requested Ad Committee to discuss which is not a good sign but eventually, I expected it will run to 70$ once they approved it.
                                      0
                                      • Move to AKBA , same sector & Potential Market higher appretiation potencial,NDA settle at mid- second quarter.
                                        0
                                    • anyone nows why the big dip ?
                                      0
                                      • missed profit
                                        0
                                      • they did not get approved by fda amd missed profits
                                        0
                                    • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
                                      0
                                      • but who tells you these impossible things
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.